§
Engagement 04 — Health & medtech
Taiwanese medtech diagnostics, Series B
Wanted to commercialise a diagnostic in the UAE and KSA without standing up a regional team.
Regional friction
- Regulatory pathways differ market-to-market
- Reimbursement uncertainty
- Distribution-only is risky
Approach
- A01Readiness brief covering MOH/DHA/SFDA pathways and timing.
- A02Distribution + regulatory partner shortlist (separate vendors).
- A03Embedded representation for first 12 months post-clearance.
Output
Distribution and regulatory partners aligned in UAE; KSA pathway scoped.